Pfizer
Trade Pfizer 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About PFE
Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.
PFE Key Statistics
Stock Snapshot
As of today, Pfizer(PFE) shares are valued at $26.51. The company's market cap stands at 150.6B, with a P/E ratio of 19.76 and a dividend yield of 6.4%.
During the trading session on 2026-04-28, Pfizer(PFE) shares reached a daily high of $28.02 and a low of $26.32. At a current price of $26.51, the stock is +0.7% higher than the low and still -5.4% under the high.
Trading volume for Pfizer(PFE) stock has reached 58.08M, versus its average volume of 34.58M.
Over the past 52 weeks, Pfizer(PFE) stock has traded between a high of $28.75 and a low of $21.97.
Over the past 52 weeks, Pfizer(PFE) stock has traded between a high of $28.75 and a low of $21.97.
PFE News
Key Points Pfizer's growth rate has tanked in recent years, and investors remain concerned about the future. The company has been loading up on acquisitions t...
Morgan Stanley notes that Pfizer (PFE) announced that it has now reached settlement with all three Vyndamax generic filers, extending the U.S. exclusivity of Vy...
10:18 EDT BridgeBio (BBIO) jumps 12% to $83.18 as Pfizer (PFE) confirms tafamidis settlement Published first on TheFly – the ultimate source for real-time, mar...
Analyst ratings
50%
of 30 ratingsMore PFE News
Pfizer (PFE) announced that it has entered into settlement agreements with generic drug manufacturers Dexcel Pharma, Hikma Pharmaceuticals and Cipla Ltd, regard...
Analyst Asad Haider of Goldman Sachs maintained a Hold rating on Pfizer, reducing the price target to $26.00. Claim 55% Off TipRanks Unlock hedge fund-level dat...
Pfizer (PFE) is back in focus after unveiling extensive new oncology data at the American Society of Clinical Oncology meeting and securing FDA Priority Review...
Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...
The analyst who called NVIDIA in 2010 just named his top 10 stocks and Conagra Brands wasn't one of them. Get them here FREE . This post may contain links from...
The Bristol Myers Squibb-Pfizer (BMY) – Pfizer (PFE) Alliance announced the launch of a collaboration with Mark Cuban Cost Plus Drug Company to offer Eliquis, o...
Pfizer (NYSE:PFE) reported positive Phase 2b results for its GLP-1 anti-obesity candidate PF-08653944, targeting once-monthly dosing. The company outlined plan...